Antiviral Drugs Market Driven By Increasing Geriatric Population & Human Immunodeficiency Virus (HIV) Infections | Grand View Research, Inc.

June 21 17:20 2021
Antiviral Drugs Market Driven By Increasing Geriatric Population & Human Immunodeficiency Virus (HIV) Infections | Grand View Research, Inc.

“Grand View Research, Inc. – Market Research And Consulting.”
According to a new report published by Grand View Research, increasing prevalence of viral infections such as HIV, hepatitis, respiratory syncytial virus (RSV), and influenza is expected to drive the demand for antiviral drugs.

The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of -2.3% over the forecast period. Increasing geriatric population is considered to be the major factor anticipated to drive the demand for efficient treatment of human immunodeficiency virus (HIV) infections.

According to the Centers of Disease Control and Prevention (CDC), nearly half the people diagnosed with HIV in U.S. are aged 50 and older. Furthermore, according to the data published in World Population Prospects: The 2019 Revision, one in six people globally is estimated to be over age of 65 years by 2050. In addition, one in four persons living in Northern America and Europe would be aged 65 years and above by 2050. The number of persons aged 80 years and above is estimated to triple, from 143 million in 2019 to 426 million in 2050. The increasing aging population worldwide would have a direct impact on the healthcare systems, who would have to meet the needs of the aging population. This, in turn, would drive the demand for antiviral drugs, which can be used to treat a range of viral infections.

Presence of pipeline antiviral products for HIV therapeutics is anticipated to drive the market over the forecast period. For instance, ViiV Healthcare is developing Cabotegravir/rilpivirine (long-acting injectable), which is currently under Phase III and are types of NNRTI/ INSTI drug class. In addition,GS-6207 (capsid inhibitor) and vesatolimod (TLR-7 agonist) are being developed by Gilead Sciences and are currently under Phase I trial for the treatment of HIV. Moreover, advancements in epidemiology and growing awareness of viral diseases are expected to result in a high demand for efficient treatment solutions.

According to the CDC, the prevalence of oral herpes (HSV-1) and genital herpes (HSV-2) was 47.8% and 11.9% respectively, from 2015 to 2016. The Herpes Resource Center (HRC) provides public awareness, education, and patient support. Moreover, the Hepatitis B Foundation provides information such as diagnosis, preventive measures, and treatment. Increasing preventive measures with the availability of various vaccines is expected to hinder the market growth over the forecast period. 

Browse full report with Table of Content @

Antiviral Drugs Market Report Highlights

 Reverse transcriptase inhibitors held the largest share in 2019 and is estimated to be the fastest-growing segment over the forecast period as these inhibitors slow down or prevent viral replication

DNA polymerase inhibitors was the second-largest segment in 2019 owing to its effectiveness in combating drug resistance

Generic products are estimated to be the fastest-growing segment over the forecast period owing to increased adoption of generic drugs in developing countries

Hepatitis dominated the application segment in 2019 owing to the availability of various antiviral products for its treatment

HIV is estimated to be the fastest-growing segment over the forecast period due to its increasing prevalence and incidence rate.

North America dominated the global antiviral drugs market in 2019 owing to the presence of key players in the region and the availability of a well-established healthcare infrastructure.

For Requesting a Sample Copy Please Visit @

Antiviral Drugs Market Segmentation

Grand View Research has segmented the global antiviral drugs market on the basis of drug class, type, application, and region:

Antiviral Drug Class Outlook (Revenue, USD Billion, 2016 – 2027)
    • DNA Polymerase Inhibitors
    • Reverse Transcriptase Inhibitors
    • Protease Inhibitors
    • Neuraminidase Inhibitors
    • Others

Antiviral Drugs Type Outlook (Revenue, USD Billion, 2016 – 2027)
    • Branded
    • Generics

Antiviral Drugs Application Outlook (Revenue, USD Billion, 2016 – 2027)
    • HIV
    • Hepatitis
    • Herpes
    • Influenza
    • Others

Antiviral Drugs Regional Outlook (Revenue, USD Billion, 2016 – 2027)
     North America
        • The U.S.
        • Canada
    • Europe
        • Germany
        • The U.K.
        • Spain
        • Italy
        • France

    • Asia Pacific
        • China
        • India
        • Japan
        • South Korea
    • Latin America
        • Brazil
        • Mexico
        • Argentina

        • Colombia
    • Middle East & Africa
        • Saudi Arabia
        • South Africa

        • UAE


Fill The Pre-Order Enquiry Form For The Report @

About Grand View Research

Grand View Research is a U.S. & India-based market research and consultancy firm. It is headquartered in San Francisco. We provide business insights, syndicated research reports, and customized research reports to large as well as small and medium-scale enterprises. Our database features thousands of statistics and in-depth analyses on more than 45 industries. Grand View Research’s extensive database is used by Fortune 500 companies to understand the regional as well as the global business environment.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States

Warning: count(): Parameter must be an array or an object that implements Countable in /home/indoreonlinejour/ on line 7